On this Page
- Patients with NDM-producing CRE reported to CDC as of January 6 2017, by state
- Patients with OXA-48-Type-producing CRE reported to CDC as of January 6, 2017, by state
- Patients with VIM-producing CRE reported to CDC as of January 6 2017, by state
- Patients with IMP-producing CRE reported to CDC as of January 6 2017, by state
- Patients with KPC-producing CRE reported to CDC as of January 6 2017, by state
Tracking CRE Infections
CDC is working to better understand the true number of infections caused by these organisms in the US. CRE infections are not a nationally notifiable condition. Therefore, there is not a requirement to report to CDC. CDC collects information on CRE from two surveillance systems:
Emerging Infections Program (EIP)
Healthcare Associated Infections Community Interface (HAIC) uses 10 sites across the country to determine which patients and community members have or are at risk for CRE and Acinetobacter.
National Healthcare Safety Network (NHSN) – tracks healthcare–associated infections of over 17,000 facilities nationwide.
- Surveillance Reporting for Enrolled Facilities
- Antimicrobial-Resistant Pathogens Associated with Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009–2010
Note: These maps represent only isolates reported to CDC and therefore these numbers might not reflect all the isolates in each state.
Patients with KPC-producing Carbapenem-resistant Enterobacteriaceae (CRE) reported to the Centers for Disease Control and Prevention (CDC) as of January 2017, by state
- Page last reviewed: July 8, 2015
- Page last updated: January 10, 2017
- Content source: